ReviewPsychoradiology2026
Multimodal neuroimaging and AI integration in cognitive disorders: advances, challenges, and future directions for precision medicine.
Review in Psychoradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Artificial intelligence approaches for schizophrenia prediction and its biomarkers using medical imaging data.Frontiers in psychiatry · 2026Pooled it
- Disrupted sensory interhemispheric synchronization in schizophrenia: a frequency-resolved VMHC analysis.Frontiers in psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive disorders, with dementia as a primary exemplar, present profound diagnostic and therapeutic challenges due to their complex pathologies and heterogeneous presentations. Artificial intelligence (AI), particularly when applied to multimodal neuroimaging and clinical data, offers a powerful approach to advancing precision medicine in this domain. This comprehensive review first examines foundational AI algorithms, including artificial neural networks for feature extraction, multimodal fusion strategies (e.g. early, intermediate, and late fusion) for data integration, and explainable AI (XAI) techniques to enhance clinical transparency. The core focus is on the application of these multimodal AI frameworks across the dementia care continuum, encompassing improved differential diagnosis, early detection through presymptomatic biomarkers, development of predictive models for disease progression, and optimization of patient stratification for clinical trials. Despite significant advances, persistent challenges remain, including limited generalizability across populations and protocols, data scarcity for non-Alzheimer's dementias and prodromal stages-exacerbated by demographic biases-and barriers to interpretability. We discuss solutions such as federated learning for privacy-preserving data sharing and advanced XAI techniques. Finally, we outline pivotal future directions, including intelligent sensor fusion for discovering novel early biomarkers, hybrid AI architectures combining generative and discriminative models, innovations for handling missing modalities, and robust multicenter data integration frameworks. By synthesizing these advances, this review highlights the role of multimodal AI in advancing precise diagnosis, early prediction, and therapeutic development for neurodegenerative and vascular cognitive disorders, while identifying key translational challenges for precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.